The new platform combines microfluidic lab-on-a-chip technology with physiologically relevant 3D spheroids to enable formation and long-term culture of 3D multicellular tumors / organoids for drug screening and individualized chemosensitivity testing.
Extensive testing shows that micro sizing drug-cell interactions reduces cost of experiments significantly as well as increasing productivity as it enables more experiments to be done on the same platform at the same time.
The microfluidic platform delivers precise control over the cellular microenvironment and beneficially through miniaturization, maximizes use of precious limited human cancer samples. Developed using leading-edge microsystem engineering, the platform delivers high-throughput analysis and is fully compatible with automated robotic dispensing systems. To enable customized data analysis of the results from the microfluidic platform, our academic team has also developed a suite of easy-to-use